Logo image
Back
Cardiovascular Effects of Mixed Amphetamine Salts Extended Release in the Treatment of School-Aged Children with Attention-Deficit/Hyperactivity Disorder
Journal article   Peer reviewed

Cardiovascular Effects of Mixed Amphetamine Salts Extended Release in the Treatment of School-Aged Children with Attention-Deficit/Hyperactivity Disorder

Richard Donner, M. Alex Michaels and Paul J. Ambrosini
Biological psychiatry (1969), v 61(5), pp 706-712
2007
DOI: https://doi.org/10.1016/j.biopsych.2006.05.002
PMID: 16899230
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Adderall XR ADHD cardiovascular effects children mixed amphetamine salts extended release stimulant
The cardiovascular safety of mixed amphetamine salts extended release (MAS XR) was evaluated in 2968 children 6–12 years of age with attention-deficit/hyperactivity disorder (ADHD). In this prospective, open-label, noncomparative, community-based study, subjects whose symptoms of ADHD were well controlled with stimulant medication maintained their established treatment regimens for 2 weeks before enrollment into the current study. Subjects’ regimens were then converted to an approximately equivalent once-daily dose of MAS XR 10, 20, or 30 mg/d according to a medication-conversion algorithm, which could be adjusted to 40 mg/d for optimal efficacy and tolerability. Systolic blood pressure (SBP), diastolic BP (DBP), and pulse were measured at each study visit. Twelve-lead electrocardiography was performed at screening and at the end of the extension phase or early termination. No clinically significant changes in BP or pulse were observed. Although one subject experienced a QT-prolongation interval > 25%, no clinically significant prolongation in the mean QT interval was seen. Approximately 2.5% of subjects demonstrated two consecutive SBP or DBP values > 95th percentile for age, sex, and height, and 3.6% of subjects’ pulse increased by ≥ 25 to ≥ 110 beats per minute. No serious cardiovascular adverse events or deaths occurred. In addition to demonstrated efficacy and safety, the cardiovascular profile of MAS XR showed generally small divergences from age-specific population norms that pose very limited risk in this patient population.

Metrics

12 Record Views
40 citations in Web of Science
46 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
Web of Science research areas
Neurosciences
Psychiatry
Logo image